These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 27073014)

  • 1. Prevention knowledge, risk behaviours and seroprevalence among nonurban injectors of southwest Connecticut.
    Grau LE; Zhan W; Heimer R
    Drug Alcohol Rev; 2016 Sep; 35(5):628-36. PubMed ID: 27073014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of HIV and other infections and injection behaviours among people who inject drugs in Addis Ababa, Ethiopia.
    Demissie M; Johnston LG; Muleta M; Desyebelew D; Belete W; G/Egxiabehre A; Gezahegn N; Kassa D; Aseffa Y
    Afr J AIDS Res; 2018 Sep; 17(3):259-264. PubMed ID: 30319040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seroprevalence of HIV, hepatitis B virus, and HCV among injection drug users in Connecticut: understanding infection and coinfection risks in a nonurban population.
    Akselrod H; Grau LE; Barbour R; Heimer R
    Am J Public Health; 2014 Sep; 104(9):1713-21. PubMed ID: 24134382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of needle and syringe Programmes in people who inject drugs - An overview of systematic reviews.
    Fernandes RM; Cary M; Duarte G; Jesus G; Alarcão J; Torre C; Costa S; Costa J; Carneiro AV
    BMC Public Health; 2017 Apr; 17(1):309. PubMed ID: 28399843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-border injection drug use and HIV and hepatitis C virus seropositivity among people who inject drugs in San Diego, California.
    Horyniak D; Wagner KD; Armenta RF; Cuevas-Mota J; Hendrickson E; Garfein RS
    Int J Drug Policy; 2017 Sep; 47():9-17. PubMed ID: 28683432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011-14).
    Wenz B; Nielsen S; Gassowski M; Santos-Hövener C; Cai W; Ross RS; Bock CT; Ratsch BA; Kücherer C; Bannert N; Bremer V; Hamouda O; Marcus U; Zimmermann R;
    BMC Public Health; 2016 Sep; 16(1):927. PubMed ID: 27595567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High prevalence of HIV, HBsAg and anti-HCV positivity among people who injected drugs: results of the first bio-behavioral survey using respondent-driven sampling in two urban areas in Mozambique.
    Semá Baltazar C; Horth R; Boothe M; Sathane I; Young P; Chitsondzo Langa D; Condula M; Ricardo H; Dengo Baloi L; Cummings B; Schaad N; Gouveia L; Teodoro E; Raymond HF
    BMC Infect Dis; 2019 Dec; 19(1):1022. PubMed ID: 31791273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk behaviours and viral infections among drug injecting migrants from the former Soviet Union in Germany: Results from the DRUCK-study.
    Derks L; Gassowski M; Nielsen S; An der Heiden M; Bannert N; Bock CT; Bremer V; Kücherer C; Ross S; Wenz B; Marcus U; Zimmermann R;
    Int J Drug Policy; 2018 Sep; 59():54-62. PubMed ID: 30005420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An urgent need to scale-up injecting drug harm reduction services in Tanzania: prevalence of blood-borne viruses among drug users in Temeke District, Dar-es-Salaam, 2011.
    Bowring AL; Luhmann N; Pont S; Debaulieu C; Derozier S; Asouab F; Toufik A; van Gemert C; Dietze P; Stoove M
    Int J Drug Policy; 2013 Jan; 24(1):78-81. PubMed ID: 23036650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV and hepatitis C prevalence, and related risk behaviours among people who inject drugs in three cities in Croatia: Findings from respondent-driven sampling surveys.
    Handanagic S; Bozicevic I; Civljak M; Dominkovic Z; Sevic S; Barbaric J; Nemeth Blazic T; Dakovic Rode O; Begovac J
    Int J Drug Policy; 2016 Jun; 32():57-63. PubMed ID: 27160504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Injection drug use, HIV/HCV, and related services in nonurban areas of the United States: A systematic review.
    Paquette CE; Pollini RA
    Drug Alcohol Depend; 2018 Jul; 188():239-250. PubMed ID: 29787966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significant decrease in injection risk behaviours among participants in a needle exchange programme.
    Kåberg M; Karlsson N; Discacciati A; Widgren K; Weiland O; Ekström AM; Hammarberg A
    Infect Dis (Lond); 2020 May; 52(5):336-346. PubMed ID: 32072841
    [No Abstract]   [Full Text] [Related]  

  • 13. High prevalence of human immunodeficiency virus, hepatitis B and C viral infections among people who inject drugs: a potential stumbling block in the control of HIV and viral hepatitis in Tanzania.
    Kawambwa RH; Majigo MV; Mohamed AA; Matee MI
    BMC Public Health; 2020 Feb; 20(1):177. PubMed ID: 32019536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seroprevalence of HCV and HIV infection among clients of the nation's longest-standing statewide syringe exchange program: A cross-sectional study of Community Health Outreach Work to Prevent AIDS (CHOW).
    Salek TP; Katz AR; Lenze SM; Lusk HM; Li D; Des Jarlais DC
    Int J Drug Policy; 2017 Oct; 48():34-43. PubMed ID: 28779632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HCV prevalence and risk behaviours among injectors of new psychoactive substances in a risk environment in Hungary-An expanding public health burden.
    Tarján A; Dudás M; Wiessing L; Horváth G; Rusvai E; Tresó B; Csohán Á
    Int J Drug Policy; 2017 Mar; 41():1-7. PubMed ID: 27984762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An assessment of an HIV prevention intervention among people who inject drugs in the states of Manipur and Nagaland, India.
    Goswami P; Medhi GK; Armstrong G; Setia MS; Mathew S; Thongamba G; Ramakrishnan L; George B; Singh RK; Paranjape RS; Mahanta J
    Int J Drug Policy; 2014 Sep; 25(5):853-64. PubMed ID: 24925819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of hepatitis C virus infection among injecting drug users in Glasgow 1990-1996: are current harm reduction strategies working?
    Taylor A; Goldberg D; Hutchinson S; Cameron S; Gore SM; McMenamin J; Green S; Pithie A; Fox R
    J Infect; 2000 Mar; 40(2):176-83. PubMed ID: 10841096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of harm reduction programs on seroincidence of HIV, hepatitis B and C, and syphilis among intravenous drug users in southwest China.
    Ruan Y; Liang S; Zhu J; Li X; Pan SW; Liu Q; Song B; Wang Q; Xing H; Shao Y
    Sex Transm Dis; 2013 Apr; 40(4):323-8. PubMed ID: 23486498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of HIV/HCV/HBV infections and drug-related risk behaviours amongst IDUs recruited through peer-driven sampling in Iran.
    Zamani S; Radfar R; Nematollahi P; Fadaie R; Meshkati M; Mortazavi S; Sedaghat A; Ono-Kihara M; Kihara M
    Int J Drug Policy; 2010 Nov; 21(6):493-500. PubMed ID: 20483578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Risk behaviours and seroprevalence to HIV, HBV and HCV in patients of the AIDS information and prevention center in Valencia, Spain].
    Alfonso Gil R; Hurtado Navarro I; Espacio Casanovas A; Santos Rubio G; Tomás Dols S
    Gac Sanit; 1999; 13(1):16-21. PubMed ID: 10217673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.